Global Cervical Cancer Diagnostics and Therapeutics Market 2020- 2025 -

The "Cervical Cancer Diagnostics and Therapeutics Market - Growth, Trends, and Forecast (2020 - 2025)" report has been added to's offering.

The factors propelling the growth of the cervical cancer diagnostics and therapeutics market are favorable government initiatives toward cervical cancer prevention, growing prevalence of cervical cancer, increase of awareness regarding early diagnosis, and strong R&D from key players for cervical cancer diagnosis and drugs.

The market has been witnessing a considerable growth, which is attributed to the increasing prevalence of cervical cancer among women, worldwide. According to the World Health Organization (WHO), more than 270,000 women die every year due to cervical cancer. The cervical cancer mortality rate is higher in developing countries, due to improper detection at early stages of the disease. With the rising adoption of cervical cancer diagnostic tests for the early detection of cervical cancer, the market is expected to grow.

Increasing awareness among the general population regarding the care, prevention, and treatment of cervical cancer, rise in certain behaviors such as sex with multiple-partners and smoking, certain genetic factors, and weak immune system are all linked to the growth of the cervical cancer diagnostics and therapeutics market.

Awareness programs have helped in the growth of the market. For instance, Medicaid, the popular government insurance program, covers the screening for cervical cancers. Medicare, another widely used insurance, covers Pap test, pelvic exam, and clinical breast exam for cervical cancer screening, every two years. These programs were found to be responsible for the growth of the overall market.

Key Market Trends

Pap Smear Test Segment is Expected to Hold a Major Market Share in the Cervical Cancer Diagnostics and Therapeutics Market

  • Pap smear test, the most effective tool for the diagnosis of HPV, was found to be the most revenue-generating segment.
  • According to the World Health Organization (WHO), cervical cancer is the fourth most frequent cancer in women with an estimated 570,000 new cases in 2018 represents 6.6% of all female cancers.
  • Moreover, approximately 90% of deaths from cervical cancer occurred in low- and middle-income countries.
  • Factors, such as the increasing prevalence of HPV infection in women and the deficiency of the HPV vaccine, which does not cover all types of HPV infections, are promoting the growth of the market.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

  • North America is the largest market for cervical cancer diagnostics and therapeutics. The large market share is attributed to the high awareness about disease prevention among women in the region, as well as to the many initiatives launched to prevent cervical cancer, which have increased the reach of insurance coverage for cervical screening tests, especially for low-income women.
  • Asia-Pacific, the fastest growing market for cervical cancer diagnostic tests, attributes its growth to the increasing prevalence of cervical cancer in developing countries, including China, India, Malaysia, Japan, South Korea, and Australia.

Competitive Landscape

The cervical cancer diagnostics and therapeutics market is fragmented competitive and consists of several major players. In terms of market share, few of the major players are currently dominating the market. Companies are currently focusing on developing advanced techniques for diagnosis, such as liquid-based cytology. Some of the companies which are currently dominating the market are Abbott Laboratories, Bristol-Meyrs Squibb Company, GlaxoSmithKline PLC, Merck & Co. Inc., Pfizer Inc., Qiagen NV, Advaxis Inc., Becton, Dickinson and Company and F. Hoffmann-La Roche Ltd.

Key Topics Covered:





4.1 Market Overview

4.2 Market Drivers

4.3 Market Restraints

4.4 Porter's Five Forces Analysis


5.1 By Diagnostic Test

5.1.1 Pap Smear Test

5.1.2 HPV Test

5.1.3 Colposcopy

5.1.4 Biopsy and Endocervical Curettage

5.1.5 Other Diagnostic Tests

5.2 By Therapeutic

5.2.1 Avastin (Bevacizumab)

5.2.2 Blenoxane (Bleomycin)

5.2.3 Hycamtin (Topotecan Hydrochloride)

5.2.4 Gemcitabine-Cisplatin

5.2.5 Vaccines Gardasil Cevarix

5.2.6 Other Therapeutics

5.3 By End User

5.3.1 Hospitals

5.3.2 Specilty Clinics

5.3.3 Cancer and Radiation Therapy Centers

5.3.4 Diagnostic Centers

5.4 Geography



Companies Mentioned

  • Abbott Laboratories
  • Bristol-Meyrs Squibb Company
  • GlaxoSmithKline PLC
  • Merck & Co. Inc.
  • Pfizer Inc.
  • Qiagen NV
  • Advaxis Inc.
  • Becton, Dickinson and Company
  • F. Hoffmann-La Roche Ltd

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

View source version on

Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900